Biologically Active Small Molecules

15(R)-HEDE is isolated by the chromatographic resolution of (&plusmn)15-HEDE. There are no reports of biological activity associated with 15(R)-HEDE in the literature.

15(R)-HEDE is isolated by the chromatographic resolution of (&plusmn)15-HEDE. There are no reports of biological activity associated with 15(R)-HEDE in the literature.

15(R)-HEDE is isolated by the chromatographic resolution of (&plusmn)15-HEDE. There are no reports of biological activity associated with 15(R)-HEDE in the literature.

15(R)-HEDE is isolated by the chromatographic resolution of (&plusmn)15-HEDE. There are no reports of biological activity associated with 15(R)-HEDE in the literature.

15(R)-HETE is produced when aspirin-inhibited COX-2 is incubated with arachidonic acid. The clinical significance of 15(R)-HETE and its potential downstream metabolites is the subject of current investigations.

15(R)-HETE is produced when aspirin-inhibited COX-2 is incubated with arachidonic acid. The clinical significance of 15(R)-HETE and its potential downstream metabolites is the subject of current investigations.

15(R)-HETE is produced when aspirin-inhibited COX-2 is incubated with arachidonic acid. The clinical significance of 15(R)-HETE and its potential downstream metabolites is the subject of current investigations.

Iloprost is a second generation structural analog of prostacyclin (PGI2) with about ten-fold greater potency than the first generation stable analogs, typified by carbaprostacyclin. Iloprost binds with equal affinity to the human recombinant IP and

Iloprost is a second generation structural analog of prostacyclin (PGI2) with about ten-fold greater potency than the first generation stable analogs, typified by carbaprostacyclin. Iloprost binds with equal affinity to the human recombinant IP and

Iloprost is a second generation structural analog of prostacyclin (PGI2) with about ten-fold greater potency than the first generation stable analogs, typified by carbaprostacyclin. Iloprost binds with equal affinity to the human recombinant IP and

Iloprost is a second generation structural analog of prostacyclin (PGI2) with about ten-fold greater potency than the first generation stable analogs, typified by carbaprostacyclin. Iloprost binds with equal affinity to the human recombinant IP and

An aspirin-triggered lipoxin that inhibits LTB4-induced chemotaxis, adherence, and transmigration of the neutrophils with twice the potency of LXA4 demonstrating activity in the nM range.